Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00HBR
|
||||
| Former ID |
DIB015545
|
||||
| Drug Name |
AIKO-150
|
||||
| Synonyms |
Opioid neutral antagonists (iv, pain), Aiko Biotechnology; 6-beta-naltrexol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Opiate dependence [ICD9: 304; ICD10:F11] | Phase 1 | [1] | ||
| Company |
Aiko Biotechnology Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H25NO4
|
||||
| Canonical SMILES |
c1cc(c2c3c1C[C@@H]1[C@]4([C@@]3([C@H]([C@@H](CC4)O)O2)C<br />CN1CC1CC1)O)O
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Mu-type opioid receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Estrogen signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Enkephalin release | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Peptide GPCRs | |||||
| Opioid Signalling | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00829777) Safety Study of Intravenous 6??Naltrexol (AIKO-150) in Opioid-Dependent Subjects. U.S. National Institutes of Health. | ||||
| REF 2 | Clinical pipeline report, company report or official report of signaturerx. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.